Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI)

Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and TAS 102) no longer have treatment options available while maintaining a good performance status which would allow them to receive a new treatment

  • 25 views
  • 03 Feb, 2022
  • 11 locations
Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.

adenocarcinoma of prostate
metastasis
adenocarcinoma
  • 4 views
  • 23 Jan, 2021
  • 1 location
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

ccnd1
carcinoma of oral cavity
oral cavity cancer
docetaxel
renal function
  • 19 views
  • 24 Feb, 2022
  • 1 location
Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive HER2-positive Metastatic Breast

and all biologic approach to the treatment of HR+, HER2+ metastatic breast cancer. Additionally, the researchers aim to examine potential biomarkers of response to palbociclib including cyclin D1

metastasis
HER2
ki-67
mammogram
anastrozole
  • 38 views
  • 09 Jul, 2021
  • 7 locations
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

supported by histology and over expression of cyclin D1 or by FISH (fluorescent in situ hybridization). In the proposed study, the primary endpoint is to estimate the biological response rate of the

cyclin d1
chop regimen
mantle cell lymphoma
vincristine
cyclophosphamide
  • 0 views
  • 24 Sep, 2021
  • 1 location
A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

biomarkers than those who receive placebo. Cyclin D1 will serve as the primary biomarker. This investigation will determine whether subjects randomized to UAB30 have an increase in all trans-retinoic

menstrual period
skin cancer
all trans-retinoic acid
melanoma skin
tubal ligation
  • 0 views
  • 23 Sep, 2022
  • 1 location
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

mechanisms have been described: (i) Amplification or overexpression of cyclin D1, (ii) Amplification of CDK4, (iii) Activating mutation of CDK4, and (iv) Loss of the CDK4 inhibitor, p16 (CDKN2A). Human

intensity-modulated radiation therapy
cetuximab
mouth cancer
dental caries
locally advanced squamous cell carcinoma
  • 82 views
  • 31 Jan, 2022
  • 1 location
A Study of Abemaciclib in Recurrent Glioblastoma

This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib

karnofsky performance status
temozolomide
tumor progression
MRI
recurrent disease
  • 357 views
  • 04 Oct, 2022
  • 4 locations
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor …

glomerular filtration rate
metastasis
cancer chemotherapy
systemic therapy
blood transfusion
  • 11 views
  • 23 Apr, 2022
  • 4 locations
9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

metastasis
cancer chemotherapy
lomustine
MRI
HER2
  • 795 views
  • 29 May, 2022
  • 10 locations